What is Dren Bio?
Dren Bio operates at the intersection of advanced protein engineering and clinical medicine. The company specializes in developing technologies designed to deplete cells, protein aggregates, and other pathogenic agents that drive disease progression. While its primary focus remains on hematologic neoplasms and solid cancers, the firm is actively exploring applications in auto-immune disorders and protein aggregation diseases. By leveraging a team of seasoned research and development professionals, Dren Bio is building a scalable platform capable of transforming how complex diseases are treated at the molecular level.
How much funding has Dren Bio raised?
Dren Bio has raised a total of $65M across 1 funding round:
Series B
$65M
Series B (2022): $65M with participation from Pfizer, ArrowMark Partners, Aisling Capital, SR One, Taiho Ventures, 8VC, HBM Healthcare Investments, and Revelation Partners
Key Investors in Dren Bio
Pfizer
Pfizer Inc. is a global biopharmaceutical leader dedicated to discovering and delivering innovative medicines and vaccines that address the world's most significant health challenges.
SR One
SR One is a transatlantic biotechnology venture capital firm that partners with scientific teams to translate innovative discoveries into new medicines, often providing hands-on strategic support.
8VC
8VC is a prominent technology investment firm that manages significant committed capital, focusing on visionary teams building industry-transforming companies across healthcare and Bio-IT sectors.
What's next for Dren Bio?
With the successful closure of this major enterprise-level funding, Dren Bio is poised to transition into a more aggressive phase of clinical development. The strategic roadmap likely involves advancing lead programs through regulatory milestones while simultaneously broadening the scope of its research into new therapeutic areas. As the company scales, the focus will shift toward validating its protein engineering technologies in human trials, potentially setting the stage for future partnerships or commercialization efforts. The backing from a diverse syndicate of life sciences investors provides not only capital but also the operational expertise required to navigate the complexities of the global biopharmaceutical landscape.
See full Dren Bio company page
